The European Network for IgE-Mediated Autoimmunity and Autoallergy (ENIGMA) initiative

Pavel Kolkhir,Sabine Altrichter,Fariza Mishaal Saiema Badloe,Hafsa Belasri,Nicolas Charles,Shauni De Vriese,Jan Gutermuth,Lisa Huygen,Emek Kocatürk,Inge Kortekaas Krohn,Melba Muñoz,Sherezade Moñino-Romero,Laurent L. Reber,Jörg Scheffel,Carolin Steinert,Yi-Kui Xiang,Marcus Maurer
DOI: https://doi.org/10.1038/s41591-024-02819-9
IF: 82.9
2024-03-02
Nature Medicine
Abstract:Chronic inflammatory diseases (CIDs) affect millions of people, and have devastating impacts on individuals, households, health systems and economic costs. Approximately 60% of the adult population in the USA (nearly 150 million people) are living with at least one chronic condition, mostly CIDs, and 42% have more than one such condition 1 . Autoimmune CIDs such as systemic lupus erythematosus (SLE) are ranked among the top 20 leading causes of death in young women, highlighting the urgent need to reduce disease burden 2 . Allergic CIDs (such as atopic dermatitis and asthma) and non-allergic chronic inflammatory skin diseases (such as chronic spontaneous urticaria (CSU)), together affect up to 30% of the global population and have a substantial impact on quality of life and productivity at school and work 3 . The management of these diseases relies mostly on treatments aimed at reducing or preventing signs and symptoms, rather than preventing or slowing disease progression or curing the disease. In many patients with psoriasis, rheumatoid arthritis or atopic dermatitis who have received targeted treatment with biologics or JAK inhibitors, withdrawal of the drug leads to the recurrence of symptoms within weeks or months 4 . In some cases, life-long treatment with anti-inflammatory drugs is needed to control chronic inflammation.
biochemistry & molecular biology,cell biology,medicine, research & experimental
What problem does this paper attempt to address?